Source: CureToday articles
Data from the AQUILA study support the use of fixed-duration subcutaneous Darzalex Faspro as an early treatment option in high-risk smoldering myeloma.
Recent Content
- (no title)
- (no title)
- (no title)
- Prostate cancer tool may cut risk for women in radiation therapy
- Predicting adverse events for risk stratification of chemotherapy based stem cell mobilization in multiple myeloma
- (no title)
- (no title)
- (no title)
- FDA OKs multiple myeloma combo for all newly diagnosed patients
- Venous thromboembolism in patients with multiple myeloma treated with B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy: A systematic review